Danaher Corporation DHR
Regular-session close
After hours · Nov 13, 5:21 PM ET
- YTD
- +1.79%
- 1 year
- +5.34%
Discussion (160)
Sign in to join the discussion
April 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company's previously communicated guidance range.
For the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%. The better-than-expected performance was broad-based across the portfolio, with particular strength in Life Sciences and Diagnostics.
DHR....
DANAHER PROVIDES UPDATE ON FIRST QUARTER 2021 FINANCIAL PERFORMANCE
WASHINGTON, April 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company's previously communicated guidance range.
For the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%. The better-than-expected performance was broad-based across the portfolio, with particular strength in Life Sciences and Diagnostics.
DANAHER PROVIDES UPDATE ON FIRST QUARTER 2021 FINANCIAL PERFORMANCE
WASHINGTON, April 13, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that it expects first quarter 2021 core revenue growth to be above the high-end of the Company's previously communicated guidance range.
For the quarter ended April 2, 2021, the Company expects revenue growth to be approximately 57.0% and non-GAAP core revenue growth including Cytiva to be approximately 29.0%. The better-than-expected performance was broad-based across the portfolio, with particular strength in Life Sciences and Diagnostics.
Earnings will greatly exceed target. DHR will raise guidance for rest of year. It will be huge according to their release statement earlier this week.
DHR raised Q1 guidance to overachieve high end of target. My expectations are huge numbers next Thursday PLUS raised guidance for the remainder of the year. Stock is up about 3% for year. Expect minimum average year increase of 12% price and will probably return 18-20% this year. That puts PT at >$275 eoy.
Now is the time to load up, before next weeks blowout earnings. DHR $250+ by next Friday.
DHR has been a core holding of mine for 15 years. I was a director there. They just dont fail. It is a shareholders dream foundation stock. 265-275 eoy.
I have never seen DHR stock act like this, in 20 years. Whats going on? Is it just too high valuation?
Execs selling shares in DHR is entirely normal and should have zero bearing on the price of this stock. The amount of options awarded to them, the time limit to exercise, and taxes all are considered when deciding to exercise the options. Other companies this would be a warning sign. Not with DHR. I was a Director there for 7 years.
One of the best companies to own, period. I was a director their for 7 years. The culture produces results.
